CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 310 enrolled
Drug / intervention
K-Lens (generic name not established) and Ketotifen +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00569777
NCT00569777Phase 3Completed

A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers

Vistakon Pharmaceuticals·interventional·Posted Dec 7, 2007·Updated Mar 6, 2015

In Brief

A Phase 3 clinical trial evaluating K-Lens (generic name not established) and Ketotifen and Placebo Lens for Allergic Conjunctivitis. Completed, enrolled 310 participants across 3 sites.

Detailed Summary

The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 7, 2007
Enrollment StartOct 1, 2007
Primary CompletionFeb 1, 2008
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.6 years ago

Interventions

K-Lens (generic name not established) and Ketotifendevice

combination drug-device product: contact lens (device) and anti-allergy drug

Placebo Lensdevice

contact lens without drug